More Lessons Learned from the STEP-BD Study (Course MD01.19)
Published on November 24, 2008 Audio Interview
Published on November 24, 2008 Audio Interview
Click here to view our current activities in Psychiatry.
In this audio interview, Drs. Michael E. Thase and A. John Rush explore STEP-BD’s randomized clinical trial results, largest ancillary study findings, and evidence-based recommendations, all of which have implications for treating patients with bipolar disorder effectively. This course is part of the The Advanced Certificate Program: Management of Mood Disorders
.
A. John Rush, MD
- Professor of Psychiatry and ~Clinical Sciences
- Vice Chair, Department of Clinical ~Sciences
- University of Texas Southwestern ~Medical Center
- Dallas, Texas
- Current Affiliation:
- Vice Dean, Clinical Sciences
- Duke-NUS Graduate Medical School Singapore
Michael E. Thase, MD
- Professor of Psychiatry
- Director, Mood and Anxiety Disorders
- Treatment and Research Program
- University of Pennsylvania
- Department of Psychiatry
- Philadelphia, Pennsylvania
Michael E. Thase, MD, has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
A. John Rush, MD, has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.
Michael E. Thase, MD, has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
Available for CME:
Physicians
Publish Date: Nov 24, 2008 Termination Date: Nov 24, 2009Estimated time for completion of this activity:
Target Audience
This activity is designed for practicing psychiatrists and other interested medical specialists who are a part of the care continuum of patients with mood disorders.
Activity Goal
The goal of this CME activity is to examine and disseminate current and emerging strategies for treating and managing patients with mood disorders—unipolar major depression and bipolar disorder.
Learning Objective (s)
- Assess the efficacy and safety of therapies to determine which therapeutic regimens are most appropriate for specific patients with mood disorders for improved outcomes.
- Evaluate current controversies and emerging and current treatment regimens to formulate practical strategic interventions that reflect the most up-to-date science and insights, and improve patient response in the treatment of specific mood disorders.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Instructions
To obtain CME credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
A. John Rush, MD has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.
Michael E. Thase, MD has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
Peer Reviewer has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Dwight L. Evans, MD has received grant/research support from the National Institute of Mental Health; and is a consultant for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb/Otsuka, Eli Lilly and Company, Forest Pharmaceuticals, Inc, Neuronetics, Inc, Pamlab, LLC, and Wyeth Pharmaceuticals.
A. John Rush, MD has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.
Michael E. Thase, MD has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Additional funding provided by
Projects In Knowledge
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME:
Physicians
Publish Date: Nov 24, 2008 Termination Date: Nov 24, 2009Estimated time for completion of this activity:
Target Audience
This activity is designed for practicing psychiatrists and other interested medical specialists who are a part of the care continuum of patients with mood disorders.
Activity Goal
The goal of this CME activity is to examine and disseminate current and emerging strategies for treating and managing patients with mood disorders—unipolar major depression and bipolar disorder.
Learning Objective (s)
- Assess the efficacy and safety of therapies to determine which therapeutic regimens are most appropriate for specific patients with mood disorders for improved outcomes.
- Evaluate current controversies and emerging and current treatment regimens to formulate practical strategic interventions that reflect the most up-to-date science and insights, and improve patient response in the treatment of specific mood disorders.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Instructions
To obtain CME credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
A. John Rush, MD has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.
Michael E. Thase, MD has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
Peer Reviewer has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Dwight L. Evans, MD has received grant/research support from the National Institute of Mental Health; and is a consultant for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb/Otsuka, Eli Lilly and Company, Forest Pharmaceuticals, Inc, Neuronetics, Inc, Pamlab, LLC, and Wyeth Pharmaceuticals.
A. John Rush, MD has received grant/research support from the National Institute of Mental Health and Stanley Medical Research Institute; is a consultant for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb/Otsuka, Cyberonics, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Magellan Health Services, Merck & Co, Inc, Ono Pharmaceuticals, Organon USA, Inc, Pamlab, LLC, and Pfizer Inc; and is on the speakers bureau for Cyberonics, Inc, Forest Pharmaceuticals, Inc, Otsuka Pharmaceutical Group, and Pfizer Inc.
Michael E. Thase, MD has received grant/research support from Eli Lilly and Company and Sepracor Inc; is a consultant for AstraZeneca, Bristol-Myers Squibb, Cephalon, Inc, Cyberonics, Inc, Eli Lilly and Company, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, MedAvante, Inc, Neuronetics, Inc, Novartis Pharmaceuticals Corporation, Organon USA, Inc, Sepracor Inc, Shire Pharmaceuticals, Supernus Pharmaceuticals, and Wyeth Pharmaceuticals; is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Cyberonics, Inc, Eli Lilly and Company, GlaxoSmithKline, Organon USA, Inc, Sanofi-Aventis, and Wyeth Pharmaceuticals; and owns stock in MedAvante, Inc.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Additional funding provided by
Projects In Knowledge
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



